Guidance for submission for food additive evaluations

EFSA Journal

Volumn 10, Issue 7, 2012, Pages

[No Author Info available]

Author keywords

Application; EFSA guidance; Food additives; Risk assessment; Tiered approach; Toxicological studies

Indexed keywords

EID: 85049298975     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2012.2760     Document Type: Note

References (77)

1. Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau; A, Aptula A, Bal-Price; A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy; U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Leite SB, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tähti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM., 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects. Arch Toxicol. 85(5):367–485. doi: 10.1007/s00204-011-0693-2.
2. Bohets H, Annaert P, Mannens G, 2001. Strategies for absorption screening in drug discovery and development. Current Topics in Medicinal Chemistry 1, 367–383.
3. Bokkers, BGH, Slob W, 2007. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach. Critical Reviews in Toxicology 37, 355–373.
4. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D, Farland W, 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol. 36:781–92.
5. Boobis AR, Doe JE, Heinrich-Hirsch; B, Meek ME, Munn S, Ruchirawat M, Schlatter J, Seed J, Vickers C, 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol. 38:87–96.
6. Bus JS, Reitz RH, 1992. Dose-dependent metabolism and dose setting in chronic studies. Toxicology Letters 64–65, 669–676.
7. Counts JL, Goodman JI, 1995. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay-dose influences mechanism. Regulatory Toxicology and Pharmacology 21, 418–421.
8. Creton S, Billington R, Davies W, Dent MP, Hawksworth GM, Parry S, Travis KZ, 2009. Application of toxicokinetics to improve chemical risk assessment: implications for the use of animals. Regulatory Toxicology and Pharmacology 55, 291–9.
9. De Flora S, Izzotti A, 2007. Mutagenesis and cardiovascular diseases. Molecular mechanisms, risk factors, and protective factors. Mutat Res. 621(1–02):5–17.
10. Dorne JMC, Renwick AG, 2005. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicological Sciences 86, 20–26.
11. EC (European Commission), 1997. Reports on Tasks for scientific co-operation. Task 4.2. Report on Methodologies for the Monitoring of Food Additive Intake across the European Union. DG Industry.
12. EC (Commission of the European Communities), 2001. Report from the Commission on dietary food additive intake in the European Union (542 final).
13. EC (European Commission), Joint Research Centre, 2008. REACH and the need for Intelligent Testing Strategies.
14. ECHA, 2008. Guidance for the Implementation of REACH. Guidance on information requirements and chemical safety assessment. Chapter R.7.a: Endpoint specific guidance. Section R.7.7 Mutagenicity and carcinogenicity, p377. European Chemicals Agency, Helsinki. Available at: guidance.echa.europa.eu/docs/guidance_document/information_requirements_r7a_en.pdf?vers=02_02_10.
15. EFSA, 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA Journal 282, 1–31.
16. EFSA, 2007. Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA - Opinion of the Scientific Committee. EFSA Journal 587, 1–16.
17. EFSA, 2009a. Guidance of the Scientific Committee on a request from EFSA on the use of the benchmark dose approach in risk assessment. EFSA Journal 1150, 1–72.
18. EFSA, 2009b. Guidance on Safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements. EFSA Journal 1249, 1–19.
19. EFSA, 2009c. The Potential Risks Arising from Nanoscience and Nanotechnologies on Food and Feed Safety. EFSA Journal 958, 1–39.
20. EFSA, 2010. Scientific Opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feed. EFSA Journal 2011;9(5):2140 [36 pp].
21. EFSA, 2011a. Guidance on the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain. EFSA Journal 2010; 8(7):1700
22. EFSA, 2011b. Scientific Opinion of the Scientific Panel on Genetically Modified Organisms (GMO) on the Guidance on the risk assessment of genetically modified microorganisms and their food and feed products or EFSA guidance on the submission of applications for authorisation of genetically modified food and feed and genetically modified plants for food or feed uses under Regulation (EC) No 1829/2003. EFSA Journal 2011;9(7):2311 [165 pp.].
23. EFSA, 2011c. Use of the EFSA Comprehensive European Food Consumption Database in exposure assessment. EFSA Journal 2097, 1–34.
24. EFSA, 2011d. Scientific opinion on genotoxicity testing strategies applicable to food and feed safety assessment. EFSA Journal 2011;9(9):2379
25. EFSA, 2012a. Statement on the applicability of the Margin of Exposure approach for the safety assessment of impurities which are both genotoxic and carcinogenic in substances added to food/feed. EFSA Journal 2012, 10 (3):2578
26. EFSA, 2012b. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012, 10 (3):2579
27. EFSA, 2012c. Exploring options for providing preliminary advice about possible human health risks based on the concept of threshold of toxicological concern (TTC). EFSA Journal 2012;10(7):2750
28. EMEA (European Medicines Agency), 2002. Guideline for Good Clinical Practice, ICH Topic E 6 (R1) (CPMP/ICH/135/95). Available at: www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf
29. Erickson RP, 2010. Somatic gene mutation and human disease other than cancer: an update. Mutat Res. 705(2):96–106.
30. European Pharmacopoeia (7th Edition) including Supplements 1 and 2, 2011. Deutscher Apotheker Verlag, Stuttgart, Germany.
31. Frank SA, 2010. Evolution in health and medicine Sackler colloquium: Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 107 Suppl 1:1725–30.
32. Gotoh Y, Kamada N, Momose D, 2005. The advantages of the Ussing chamber in drug absorption studies. Journal of Biomolecular Screening 10, 517–523.
33. Grass GM, Sweetana SA, 1988. In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharma Research 5, 372–376.
34. Gotoh Y, Kamada N, Momose D, 2005. The advantages of the Ussing chamber in drug absorption studies. J Biomol Screen. 10(5):517–23.
35. Guandalini S, Newland C, 2011. Differentiating food allergies from food intolerances. Curr Gastroenterol Rep. 13(5):426–34.
36. Hayder H, Mueller U, and Bartholomaeus A, 2011. Review of intolerance reactions to food and food additives. Int. Food Risk Anal. J. 1(2): 23–32
37. Hoeijmakers JH, 2009. DNA damage, aging, and cancer. N Engl J Med. 361(15):1475–85.IPCS, 2004 IPCS Risk Assessment Terminology. Part 1:IPCS/OECD Key Generic Terms used in Chemical Hazard/Risk Assessment. International Programme on Chemical Safety. World Health Organization, Geneva.
38. JECFA, 1972. WHO Technical Report Series, Evaluation of certain food additives and the contaminants mercury, lead, and cadmium. Sixteenth report of the Joint FAO/WHO Expert Committee on Food Additives. No. 505. World Health Organization, Geneva.
39. JECFA, 1978. Evaluation of certain food additives. Twenty-first report of the Joint FAO/WHO Expert Committee on Food Additives. No. 617. World Health Organization, Geneva.
40. JECFA, 2006. Combined Compendium of food additive specifications. Volume 4 of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization, Geneva. (ftp://ftp.fao.org/docrep/fao/009/a0691e/a0691e00a.pdf).
41. ICH, 1995. www.ich.org/products/guidelines/safety/article/safety-guidelines.html
42. IPCS, 2004. IPCS Risk Assessment Terminology (Part 1: IPCS/OECD Key Generic terms used in Chemical Hazard/Risk Assessment (www.inchem.org/documents/harmproj/harmproj/harmproj1.pdf)
43. IPCS, 2005. Chemical-specific adjustment factors for interspecies differences and human variability: Guidance document for use of data in dose/concentration response assessment (Harmonization Project Document No. 2). (whqlibdoc.who.int/publications/2005/9241546786_eng.pdf)
44. IPCS, 2006. Framework for analysing the relevance of a cancer and a non-cancer mode of action for humans. (Harmonisation project document No. 4). (www.who.int/ipcs/methods/harmonization/areas/cancer_mode.pdf)
45. IPCS, 2009. Dose-response assessment and derivation of health-based guidance values (Chapter 5). Principles and Methods for the Risk Assessment of Chemicals in Food; Environmental Health Criteria 240. (whqlibdoc.who.int/ehc/WHO_EHC_240_8_eng_Chapter5.pdf)
46. Kato T, Hayashi Y, Inoue K, Yuasa H, 2004. Functional characterization of the carrier-mediated transport system for glycerol in everted sacs of the rat small intestine. Biological & Pharmaceutical Bulletin 27, 1826–30.
47. Meek B, Renwick A, Sunich-Mullin; C, 2003. Practical application of kinetic data in risk assessment - an IPCS initiative. Toxicology Letters 138, 151–160.
48. Naumann BD, Silverman KC, Dixit R, Faria EC, Sargent EV, 2001. Case studies of categorical data-derived adjustment factors. Human and Ecological Risk Assessment 7, 61–105.
49. National Research Council, Committee on Toxicity and Assessment of Environmental Agents, 2007. Toxicity Testing in the Twenty-first Century: A Vision and a Strategy.
50. NIAID-Sponsored; Expert Panel, Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, Bahna SL, Beck LA, Byrd-Bredbenner; C, Camargo CA Jr, Eichenfield L, Furuta GT, Hanifin JM, Jones C, Kraft M, Levy BD, Lieberman P, Luccioli S, McCall KM, Schneider LC, Simon RA, Simons FE, Teach SJ, Yawn BP, Schwaninger JM, 2010. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 126(6 Suppl):S1–58.
51. OECD, 1997. OECD Guidelines for the Testing of Chemicals-Test Guideline 424, Neurotoxicity Study in Rodents (adopted 21 July, 1997). Organisation for Economic Cooperation and Development, Paris.
52. OECD, 1997. OECD Guidelines for the Testing of Chemicals-Test Guideline 471, Bacterial Reverse Mutation test (adopted 21 July, 1997). Organisation for Economic Cooperation and Development, Paris.
53. OECD, 1997. OECD Guidelines for the Testing of Chemicals-Test Guideline 474, Mammalian Erythrocyte Micronucleus Test (adopted 21 July, 1997). Organisation for Economic Cooperation and Development, Paris.
54. OECD, 1997. OECD Guidelines for the Testing of Chemicals-Test Guideline 475, Mammalian Bone Marrow Chromosome Aberration Test (adopted 21 July, 1997). Organisation for Economic Cooperation and Development, Paris.
55. OECD, 1998. OECD Guidelines for the Testing of Chemicals-Test Guideline 408, Repeated Dose 90-day Oral Toxicity Study in Rodents (adopted 21 September, 1998). Organisation for Economic Cooperation and Development, Paris.
56. OECD, 2001. OECD Guidelines for the Testing of Chemicals-Test Guideline 414, Prenatal Developmental Toxicity Study (adopted 22 January, 2001). Organisation for Economic Cooperation and Development, Paris.
57. OECD, 2007. OECD Guidelines for the Testing of Chemicals-Test Guideline 426, Developmental Neurotoxicity Study (adopted 16 October, 2007). Organisation for Economic Cooperation and Development, Paris.
58. OECD, 2008. OECD Guidelines for the Testing of Chemicals-Test Guideline 407, Repeated Dose 28-Day Oral Toxicity Study in Rodents (adopted 3 October, 2008). Organisation for Economic Cooperation and Development, Paris.
59. OECD, 2009. OECD Guidelines for the Testing of Chemicals-Test Guideline 452, Chronic Toxicity Studies (adopted 7 September, 2009). Organisation for Economic Cooperation and Development, Paris.
60. OECD, 2009. OECD Guidelines for the Testing of Chemicals-Test Guideline 453, Combined Chronic Toxicity/Carcinogenicity Studies (adopted 7 September, 2009). Organisation for Economic Cooperation and Development, Paris.
61. OECD, 2009. OECD Guidelines for the Testing of Chemicals-Test Guideline 451, Carcinogenicity Study (adopted 7 September, 2009). Organisation for Economic Cooperation and Development, Paris.
62. OECD, 2010. OECD Guidelines for the Testing of Chemicals-Test Guideline 487, In vitro Mammalian cell Micronucleus Test (adopted 22 July, 2010). Organisation for Economic Cooperation and Development, Paris.
63. OECD, 2010. OECD Guidelines for the Testing of Chemicals-Test Guideline 417, Toxicokinetics (adopted 22 July, 2010). Organisation for Economic Cooperation and Development, Paris.
64. OECD, 2011. OECD Guidelines for the Testing of Chemicals-Test Guideline 443, Extended One-Generation; Reproductive Toxicity Study (adopted 28 July, 2011). Organisation for Economic Cooperation and Development, Paris.
65. OECD, 2011. OECD Guidelines for the Testing of Chemicals-Test Guideline 488, Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays (adopted 28 July, 2011). Organisation for Economic Cooperation and Development, Paris.
66. o 116, Design and Conduct of Chronic Toxicity and Carcinogenicity Studies, supporting Test Guidelines 451, 452, 453 (13 April, 2012). Organisation for Economic Cooperation and Development, Paris.
67. Piersma AH, Rorije E, Beekhuijzen ME, Cooper R, Dix DJ, Heinrich-Hirsch; B, Martin MT, Mendez E, Muller A, Paparella M, Ramsingh D, Reaves E, Ridgway P, Schenk E, Stachiw L, Ulbrich B, Hakkert BC, 2011. Combined retrospective analysis of 498 rat multi-generation reproductive toxicity studies: on the impact of parameters related to F1 mating and F2 offspring. Reprod Toxicol. 31(4):392–401.
68. SCF, 1996. Opinion on additives in nutrient preparations for use in infant formulae, follow-on formulae and weaning foods. 7 June 1996. ec.europa.eu/food/fs/sc/scf/reports/scf_reports_40.pdf
69. SCF, 1998. Opinion of the Scientific Committee of Food on the applicability of the ADI (Acceptable Daily Intake) for food additives to infants. 17 September 1998. ec.europa.eu/food/fs/sc/scf/out13_en.html
70. SCF, 2001. Guidance on submissions for food additive evaluations by the Scientific Committee on Food. 12 July 2001 ec.europa.eu/food/fs/sc/scf/out98_en.pdf
71. Slatter MA, Gennery AR, 2010. Primary immunodeficiencies associated with DNA-repair disorders. Expert Rev. Mol. Med 12: e9.
72. Slikker WJr, Andersen ME, Bogdanffy MS, Bus JS, Cohen SD, Conolly RB, David RM, Doerrer NG, Dorman DC, Gaylor DW, Hattis D, Rogers JM, Woodrow Setzer R, Swenberg JA, Wallace K, 2004. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicology and Applied Pharmacology 201, 226–294.
73. Ussing HH, Zerahn K, 1951. Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Acta Physiologica Scandinavica 23, 110–127.
74. van Leeuwen CJ, Patlewicz GY and Worth AP, 2007. Risk Assessment of Chemicals. Intelligent testing strategies. 467–509.
75. Versantvoort CHM, Rompelberg CJM, Sips AJAM, 2000. Methodologies to study human intestinal absorption. RIVM Report 63003001.
76. WHO/IPCS, 2012. Guidance for Immunotoxicity Risk Assessment for Chemicals. (Harmonization Project Document No.10). (www.who.int/entity/ipcs/methods/harmonization/areas/guidance_immunotoxicity.pdf)
77. Wilson TH, Wiseman G, 1954. The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. Journal of Physiology 123, 116–125.